Trastuzumab emtansine (T-DM1)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TRASTUZUMAB-EMTANSINE |
|---|---|
| Type | Drug |
| Aliases | KadcylaТрастузумаб емтанзин |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | HER2-targeted antibody-drug conjugate (DM1 maytansinoid payload) |
|---|---|
| Mechanism | Trastuzumab linked to DM1 (tubulin-targeting maytansinoid) via stable linker. Internalized by HER2+ cells, releases DM1 intracellularly, microtubule-disrupting cell-cycle arrest. |
| Typical dosing | 3.6 mg/kg IV q3 weeks. Standard adjuvant 14 cycles (KATHERINE) for residual disease after neoadjuvant HER2+ therapy. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
KATHERINE: T-DM1 superior to trastuzumab in adjuvant residual-disease HER2+ post-neoadjuvant. Replaced by T-DXd as preferred 2L metastatic per DESTINY-Breast03.
Used By
Regimens
REG-TDM1-ADJUVANT- T-DM1 adjuvant (HER2+ residual disease post-neoadjuvant)